LIfT’s Technology –
A Safe, Simple & Scalable Allo Cell Therapy

N-LIfT is a new type of pre-clinical cell therapy that is simple to produce, scale, store and administer. Our aim is to develop an affordable cure for all solid tumours. N-LIfT is classified as an allogeneic ATMP, in which neutrophils derived from stem cells, originating from a single donor can provide treatments to a large number of patients. Allogeneic therapies are “off the shelf”, a more practical solution that can be administered to any patient upon diagnosis, rather than having to wait precious weeks to harvest and manufacture cells for each individual patient.


Donor screening and testing is needed to establish donor’s infectious status, genetic predisposition to pertinent diseases and susceptibility to cancer. Furthermore, only donors who demonstrate having neutrophils with N1a characteristics are invited back for G-CSF mobilised leukapheresis. These leukapheresis products are haematopoietic stem cell (HSC) rich that gives a better starting cell number for HSC selection and expansion. N1a neutrophils are derived from these donor stem cells in large-scale using LIfT’s proprietary and easy to scale manufacturing platform. The product N-LIfT is harvested, cryopreserved and stored in LIfT Biosciences cell bank to be shipped to patients in designated hospitals.

We have established partnerships with stem cell providers that give us access to over 600,000 donors, which would be enough to treat tens of millions of patients. We are also developing an iPSC dervied version of N-LIfT that would in time be expected to enable us to be independent of donors - a truly unlimited supply "off the shelf" product.